All In Biotech

Free tool

FAERS Monitor: Increlex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021839 or its brand name (Increlex, Mecasermin Recombinant). Reports on generic versions are filed under their own applications.

Reports

812

Serious

433

53% of reports

Hospitalization

221

Death reported

24

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use133
  • headache67
  • hypoglycaemia62
  • vomiting44
  • injection site pain41
  • drug dose omission40
  • blood glucose decreased36
  • pyrexia36
  • tonsillar hypertrophy36
  • fatigue34
  • product dose omission issue30
  • decreased appetite27
  • injection site pruritus25
  • injection site erythema24
  • drug ineffective22

Reports by year received

View as table
YearReports
20062
200729
200852
200916
201041
201165
201249
201323
201428
201521
201619
2017212
201860
201943
202025
202121
202225
202311
202412
202545
202613

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,347 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
tonsillar hypertrophySignal36567.1410.619,359
hypoglycaemiaSignal6233.226.11,903
blood glucose decreasedSignal3619.414.1612
injection site pruritusSignal259.76.6186
drug dose omissionSignal406.34.6173
injection site erythemaSignal245.03.474
off label useSignal1333.93.4301
injection site painSignal413.52.670
decreased appetiteSignal273.02.135
headacheSignal672.82.276
pyrexiaSignal362.72.037
product dose omission issueSignal302.61.929
vomitingSignal442.41.836
fatigue341.10.80
drug ineffective220.40.317

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.